evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews · Gut

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 25%GRADE not reported 0 · 0%Very low 2 · 50%Low 0 · 0%Moderate 1 · 25%High 0 · 0%

Infliximab combined with purine analogues vs purine analogues

Clinical relapse · Participants with Crohn's disease in remission

Infliximab combined with purine analogues probably leads to lower clinical relapse (at 48 weeks, CDAI of 150 or greater together with… compared with purine analogues (moderate certainty).

1 finding from 1 review

Infliximab combined with purine analogues vs purine analogues

Withdrawals due to adverse events · Participants with Crohn's disease in remission

It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).

1 finding from 1 review

Infliximab combined with purine analogues vs purine analogues

Serious adverse events (at 48 weeks to 2 years) · Participants with Crohn's disease in remission

It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).

1 finding from 1 review